In a welcome move, BioNTech ADR saw its Relative Strength Rating improve from 66 to 77 on Wednesday.
IBD's unique RS Rating identifies market leadership by showing how a stock's price movement over the last 52 weeks measures up against that of the other stocks in our database.
Over 100 years of market history shows that the stocks that go on to make the biggest gains tend to have an 80 or higher RS Rating in the early stages of their moves. See if BioNTech ADR can continue to rebound and clear that threshold.
How To Invest In Stocks In Both Bull And Bear Markets
BioNTech ADR is working on a consolidation with a 131.49 buy point. See if the stock can break out in volume at least 40% higher than normal.
Earnings grew 29% last quarter, up from 0% in the prior report. Revenue also increased, from -25% to 46%.
The company holds the No. 149 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Exelixis and Corcept Therapeutics are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
